Contezolid acefosamil sodium - CAS:1807365-35-0

您当前的位置：

Contezolid acefosamil sodium (Synonyms:MRX-4 sodium)

目录号 : KM12347 CAS No. : 1807365-35-0 纯度 : 98%

Data Sheet 产品使用指南

Contezolid acefosamil sodium (MRX-4) 是一种新型的恶唑烷酮，用于耐药革兰氏阳性菌引起的皮肤组织感染并发症 (cSSTI) 的抗生素。Contezolid acefosamil sodium (MRX-4) 可显著降低骨髓移植和单胺氧化酶抑制。

规格	价格	是否有货
5mg		In-stock
10mg		In-stock
50mg	询价	In-stock
100mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Kgp-IN-1 hydrochloride In-stock
Ginkgolide A In-stock
Ginkgetin In-stock
VKGILS-NH2 In-stock
7,3',4'-Tri-O-methylluteolin In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Contezolid acefosamil sodium (MRX-4), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid acefosamil sodium (MRX-4) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI).

体外研究

Contezolid (MRX-I) is highly potent against all Grampositive clinical isolates of staphylococci, streptococci, and enterococci, including MDR organisms such as MRSA, methicilline-resistant Streptococcus epidermidis (MRSE), penicillin-resistant Streptococci (PRSP), and VRE.

体内研究

Oral absorption of Contezolid (MRX-I) occurrs rapidly in mouse, rat, and dog, with peak plasma concentrations observed at 0.5−2.6 h postdose. In mouse, rat, and dog, respectively, PK parameters are determined as follows: dose-normalized C_max/dose was 524, 1065, and 259 ng/mL/(mg/kg); dose-normalized AUC_0−t/dose was 1654, 3703, and 1664 ng•h/mL/(mg/kg); T_1/2 is 1, 1.5, and 3 h; and the oral bioavailability is 69%, 109%, and 37%.
Contezolid (MRX-I) exhibits no obvious toxicity.
Contezolid (MRX-I, 100 mg/kg, once daily) significantly reduced the bacterial load in lungs compared to the untreated early and late controls.

Animal Model:	BALB/c mice infected intranasally with M. tuberculosis Erdman.
Dosage:	100, 50 (twice), 25 (twice) mg/kg.
Administration:	Gavage, once or twice daily, five days per week for four weeks.
Result:	Significantly reduced the CFU recovered from the lungs compared to the early and late control mice (P < 0.05). Twice daily MRX-I at 50mg/kg and 25 mg/kg were significantly better than the late control mice (P < 0.05). Once daily MRX-I at 100 mg/kg was significantly better than twice daily 50 mg/kg and 25 mg/kg (P < 0.05). There was no statistical difference between twice daily 50 mg/kg of MRX-I and 25mg/kg (P > 0.05).

Animal Model:	Rats.
Dosage:	20, 100, and 200/300 mg/kg/day.
Administration:	Orally twice daily.
Result:	No mortality was observed.

分子式

C₂₀H₁₇F₃N₄NaO₈P

分子量

552.33

CAS号

1807365-35-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-80°C, stored under nitrogen

溶解性数据

In Vitro:

DMSO : 180 mg/mL (325.89 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8105 mL	9.0526 mL	18.1051 mL
5 mM	0.3621 mL	1.8105 mL	3.6210 mL
10 mM	0.1811 mL	0.9053 mL	1.8105 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 4.5 mg/mL (8.15 mM); Clear solution

此方案可获得 ≥ 4.5 mg/mL (8.15 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 45.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 4.5 mg/mL (8.15 mM); Clear solution

此方案可获得 ≥ 4.5 mg/mL (8.15 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 45.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 4.5 mg/mL (8.15 mM); Clear solution

此方案可获得 ≥ 4.5 mg/mL (8.15 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 45.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。